Maze Therapeutics, Inc. (MAZE) Stock Statistics & Valuation Metrics

Maze Therapeutics, Inc. has a market cap or net worth of $1.83B. The enterprise value is $886.88M.

Maze Therapeutics, Inc. has 48,119,446 shares outstanding. The number of shares has decreased by -2.65% in one year.

Maze Therapeutics, Inc.’s return on equity (ROE) is 0.27 and return on invested capital (ROIC) is 25.09%.

The current PE Ratio of Maze Therapeutics, Inc. is ―. Maze Therapeutics, Inc.’s PEG ratio is -0.13.

In the last 12 months, Maze Therapeutics, Inc. had revenue of 167.50M and earned 52.23M in profits. Earnings per share was 0.08.

In the last 12 months, operating cash flow was -106.66M and capital expenditures -1.36M, giving a free cash flow of -108.03M billion.

Maze Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Maze Therapeutics, Inc. upcoming earnings date is Apr 6, 2026, Before Open (Confirmed).

Maze Therapeutics, Inc. as a current ratio of 9.76, with Debt / Equity ratio of 6.37%

In the past 12 months, Maze Therapeutics, Inc. has paid 1.17M in taxes.

Maze Therapeutics, Inc. EV to EBITDA ratio is 8.68, with an EV/FCF ratio of 7.06.

Maze Therapeutics, Inc. has $383.94M in cash and marketable securities with $24.18M in debt, giving a net cash position of $359.75M billion.

Gross margin is 0.00%, with operating margin of 34.38%, and net profit margin of 31.18%.

The average price target for Maze Therapeutics, Inc. is $40.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy